Go to  Advanced Search

Y-box binding protein-1 induces MET, CD44, and CD49f thereby promoting the capacity for tumour initiation.

Show full item record

Files in this item

Files Size Format Description   View
ubc_2009_fall_to_karen.pdf 3.637Mb Adobe Portable Document Format   View/Open
Title: Y-box binding protein-1 induces MET, CD44, and CD49f thereby promoting the capacity for tumour initiation.
Author: To, Karen Ka-Yan
Degree Master of Science - MSc
Program Experimental Medicine
Copyright Date: 2009
Publicly Available in cIRcle 2009-09-30
Abstract: Y-box binding protein-1 (YB-1) is an oncogenic transcription/translation factor expressed in >40% of breast cancers, where its expression correlates with enhanced tumour cell growth and drug resistance. YB-1 is also significantly associated with disease recurrence, suggesting links to tumour-initiating cells (TICs). We recently reported that YB-1 binds to the promoters of genes associated with a stem/progenitor-like phenotype through a chromatin immunoprecipitation (ChIP)-on-chip screen, including genes encoding the MET receptor, CD44, and CD49f. We first confirmed that YB-1 induces oncogene MET by activating its promoter. Further, both YB-1 and MET expression were detected in purified populations of primary human mammary progenitor cells. Similarly, we confirmed that YB-1 binds the gene promoters of reported TIC markers CD44 and the stem cell marker CD49f (α6 integrin) using conventional ChIP. Human breast TICs, reportedly CD44⁺/CD24⁻/low, self-renew, grow in mammospheres, and may evade current drug therapies, leading to increased relapse rates in patients. We observed that P-YB-1S102 co-localized to a CD44High breast cancer cell subpopulation with increased growth capacities. Silencing YB-1 down-regulated MET, CD44 and CD49f, while overexpression of wild-type (YB-1WT) or a constitutively activated form (YB-1S102D) increased MET, CD44 and CD49f transcripts and proteins. Consistent with these findings, the mammary glands of YB-1 transgenic mice had elevated CD44 and CD49f protein with associated hyperplasia. Moreover, the expression of YB-1S102D in SUM 149 cells, enhanced mammosphere formation and growth in soft agar. Conversely, silencing either CD44 or CD49f in these cells reversed YB-1S102D enhanced growth. Consistent with a role for TICs in relapse, Paclitaxel activated YB-1 and this correlated with induced CD44. Further, expression of YB-1WT enhanced mammosphere growth in the presence of Paclitaxel. Taken together, our data suggests that YB-1 induces MET, CD44, and CD49f expression which may be a part of the mechanism used to enhance tumour cell growth, disease relapse, and drug resistance.
URI: http://hdl.handle.net/2429/13392

This item appears in the following Collection(s)

Show full item record

All items in cIRcle are protected by copyright, with all rights reserved.

UBC Library
1961 East Mall
Vancouver, B.C.
Canada V6T 1Z1
Tel: 604-822-6375
Fax: 604-822-3893